The 6q25.1 locus was first identified via a genome-wide association study (GWAS) in Chinese women and marked by single nucleotide polymorphism (SNP) rs2046210, approximately 180 Kb upstream of ESR1. There have been conflicting reports about the association of this locus with breast cancer in Europeans, and a GWAS in Europeans identified a different SNP, tagged here by rs12662670. We examined the associations of both SNPs in up to 61,689 cases and 58,822 controls from forty-four studies collaborating in the Breast Cancer Association Consortium, of which four studies were of Asian and 39 of European descent. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Case-only analyses were used to compare SNP effects in Estrogen Receptor positive (ER+) versus negative (ER-) tumours. Models including both SNPs were fitted to investigate whether the SNP effects were independent. Both SNPs are significantly associated with breast cancer risk in both ethnic groups. Per-allele ORs are higher in Asian than in European studies [rs2046210: OR (A/G) = 1.36 (95% CI 1.26-1.48), p = 7.6×10-14 in Asians and 1.09 (95% CI 1.07-1.11), p = 6.8×10-18 in Europeans. rs12662670: OR (G/T) = 1.29 (95% CI 1.19-1.41), p = 1.2×10-9 in Asians and 1.12 (95% CI 1.08-1.17), p = 3.8×10-9 in Europeans]. SNP rs2046210 is associated with a significantly greater risk of ER- than ER+ tumours in Europeans [OR (ER-) = 1.20 (95% CI 1.15-1.25), p = 1.8×10-17 versus OR (ER+) = 1.07 (95% CI 1.04-1.1), p = 1.3×10-7, pheterogeneity = 5.1×10-6]. In these Asian studies, by contrast, there is no clear evidence of a differential association by tumour receptor status. Each SNP is associated with risk after adjustment for the other SNP. These results suggest the presence of two variants at 6q25.1 each independently associated with breast cancer risk in Asians and in Europeans. Of these two, the one tagged by rs2046210 is associated with a greater risk of ER- tumours. © 2012 Hein et al.

Comparison of 6q25 breast cancer hits from Asian and European genome wide association studies in the Breast Cancer Association consortium (BCAC) / Hein R.; Maranian M.; Hopper J.L.; Kapuscinski M.K.; Southey M.C.; Park D.J.; Schmidt M.K.; Broeks A.; Hogervorst F.B.L.; Bueno-de-Mesquit H.B.; Muir K.R.; Lophatananon A.; Rattanamongkongul S.; Puttawibul P.; Fasching P.A.; Hein A.; Ekici A.B.; Beckmann M.W.; Fletcher O.; Johnson N.; dos Santos Silva I.; Peto J.; Sawyer E.; Tomlinson I.; Kerin M.; Miller N.; Marmee F.; Schneeweiss A.; Sohn C.; Burwinkel B.; Guenel P.; Cordina-Duverger E.; Menegaux F.; Truong T.; Bojesen S.E.; Nordestgaard B.G.; Flyger H.; Milne R.L.; Perez J.I.A.; Zamora M.P.; Benitez J.; Anton-Culver H.; Ziogas A.; Bernstein L.; Clarke C.A.; Brenner H.; Muller H.; Arndt V.; Stegmaier C.; Rahman N.; Seal S.; Turnbull C.; Renwick A.; Meindl A.; Schott S.; Bartram C.R.; Schmutzler R.K.; Brauch H.; Hamann U.; Ko Y.-D.; Wang-Gohrke S.; Dork T.; Schurmann P.; Karstens J.H.; Hillemanns P.; Nevanlinna H.; Heikkinen T.; Aittomaki K.; Blomqvist C.; Bogdanova N.V.; Zalutsky I.V.; Antonenkova N.N.; Bermisheva M.; Prokovieva D.; Farahtdinova A.; Khusnutdinova E.; Lindblom A.; Margolin S.; Mannermaa A.; Kataja V.; Kosma V.-M.; Hartikainen J.; Chen X.; Beesley J.; Lambrechts D.; Zhao H.; Neven P.; Wildiers H.; Nickels S.; Flesch-Janys D.; Radice P.; Peterlongo P.; Manoukian S.; Barile M.; Couch F.J.; Olson J.E.; Wang X.; Fredericksen Z.; Giles G.G.; Baglietto L.; McLean C.A.; Severi G.; Offit K.; Robson M.; Gaudet M.M.; Vijai J.; Alnaes G.G.; Kristensen V.; Borresen-Dale A.-L.; John E.M.; Miron A.; Winqvist R.; Pylkas K.; Jukkola-Vuorinen A.; Grip M.; Andrulis I.L.; Knight J.A.; Glendon G.; Mulligan A.M.; Figueroa J.D.; Garcia-Closas M.; Lissowska J.; Sherman M.E.; Hooning M.; Martens J.W.M.; Seynaeve C.; Collee M.; Hall P.; Humpreys K.; Czene K.; Liu J.; Cox A.; Brock I.W.; Cross S.S.; Reed M.W.R.; Ahmed S.; Ghoussaini M.; Pharoah P.D.; Kang D.; Yoo K.-Y.; Noh D.-Y.; Jakubowska A.; Jaworska K.; Durda K.; Zlowocka E.; Sangrajrang S.; Gaborieau V.; Brennan P.; McKay J.; Shen C.-Y.; Yu J.-C.; Hsu H.-M.; Hou M.-F.; Orr N.; Schoemaker M.; Ashworth A.; Swerdlow A.; Trentham-Dietz A.; Newcomb P.A.; Titus L.; Egan K.M.; Chenevix-Trench G.; Antoniou A.C.; Humphreys M.K.; Morrison J.; Chang-Claude J.; Easton D.F.; Dunning A.M.. - In: PLOS ONE. - ISSN 1932-6203. - STAMPA. - 7:(2012), pp. e42380-e42380. [10.1371/journal.pone.0042380]

Comparison of 6q25 breast cancer hits from Asian and European genome wide association studies in the Breast Cancer Association consortium (BCAC)

Hein R.;Hein A.;Kerin M.;Zhao H.;Manoukian S.;Wang X.;Severi G.;Miron A.;Cross S. S.;Kang D.;
2012

Abstract

The 6q25.1 locus was first identified via a genome-wide association study (GWAS) in Chinese women and marked by single nucleotide polymorphism (SNP) rs2046210, approximately 180 Kb upstream of ESR1. There have been conflicting reports about the association of this locus with breast cancer in Europeans, and a GWAS in Europeans identified a different SNP, tagged here by rs12662670. We examined the associations of both SNPs in up to 61,689 cases and 58,822 controls from forty-four studies collaborating in the Breast Cancer Association Consortium, of which four studies were of Asian and 39 of European descent. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Case-only analyses were used to compare SNP effects in Estrogen Receptor positive (ER+) versus negative (ER-) tumours. Models including both SNPs were fitted to investigate whether the SNP effects were independent. Both SNPs are significantly associated with breast cancer risk in both ethnic groups. Per-allele ORs are higher in Asian than in European studies [rs2046210: OR (A/G) = 1.36 (95% CI 1.26-1.48), p = 7.6×10-14 in Asians and 1.09 (95% CI 1.07-1.11), p = 6.8×10-18 in Europeans. rs12662670: OR (G/T) = 1.29 (95% CI 1.19-1.41), p = 1.2×10-9 in Asians and 1.12 (95% CI 1.08-1.17), p = 3.8×10-9 in Europeans]. SNP rs2046210 is associated with a significantly greater risk of ER- than ER+ tumours in Europeans [OR (ER-) = 1.20 (95% CI 1.15-1.25), p = 1.8×10-17 versus OR (ER+) = 1.07 (95% CI 1.04-1.1), p = 1.3×10-7, pheterogeneity = 5.1×10-6]. In these Asian studies, by contrast, there is no clear evidence of a differential association by tumour receptor status. Each SNP is associated with risk after adjustment for the other SNP. These results suggest the presence of two variants at 6q25.1 each independently associated with breast cancer risk in Asians and in Europeans. Of these two, the one tagged by rs2046210 is associated with a greater risk of ER- tumours. © 2012 Hein et al.
2012
7
e42380
e42380
Hein R.; Maranian M.; Hopper J.L.; Kapuscinski M.K.; Southey M.C.; Park D.J.; Schmidt M.K.; Broeks A.; Hogervorst F.B.L.; Bueno-de-Mesquit H.B.; Muir ...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1187371
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 51
  • ???jsp.display-item.citation.isi??? 46
social impact